Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJ

Published 11/23/2019, 03:12 PM
Updated 11/23/2019, 03:12 PM
© Reuters. FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel

(Reuters) - Swiss drugmaker Novartis AG (S:NOVN) is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co (O:MDCO) for about $7 billion, the Wall Street Journal reported on Saturday.

The deal, in which Novartis has agreed to pay $85 a share, could be announced this weekend, the Journal reported, citing people familiar with the matter.

Going by a fully diluted share count, the agreement is worth about $10 billion, according to the report.

Novartis declined to comment. The Medicines Co did not respond to a request for comment on Saturday.

The deal could broaden the Swiss drugmaker's cabinet of heart medicines and shore up growth threatened by patent expirations.

Novartis has been hunting for a $5 billion acquisition in the United States, two banking sources told Reuters earlier this week without identifying a target.

New Jersey-based The Medicines Co's top drug candidate is cholesterol-lowering drug inclisiran for heart patients. Novartis has historically had a strong cardiovascular drug franchise, but lost ground when Diovan, once a $6 billion-per-year seller, lost patent protection in 2012 and left the company without an immediate, innovative follow-up product.

Novartis has since been building up its portfolio, which now includes Entresto, a $1 billion seller for heart failure, as well as an experimental RNA-targeting molecule from Ionis Pharmaceuticals (O:IONS) that it licensed earlier this year for $150 million.

© Reuters. FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.